| Bioactivity | SBFI-26 is a selective and competitive inhibitor of fatty acid binding proteins FABP5 and FABP7, with Kis of 0.9 µM and 0.4 µM for FABP5 and FABP7, respectively. SBFI-26 produces anti-nociceptive and anti-inflammatory effects[1][2]. | ||||||||||||
| Target | Ki: 0.9 μM (FABP5), 0.4 µM (FABP7) | ||||||||||||
| Invitro | SBFI-26 binds to the canonical ligand-binding pocket of FABP5[1].SBFI-26 significantly inhibits cellular AEA accumulation[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SBFI-26 相关抗体: | ||||||||||||
| In Vivo | SBFI-26 (20 mg/kg, i.p.) significantly reduces carrageenan-induced thermal hyperalgesia and paw edema[2].SBFI-26 produces antinociceptive and anti-inflammatory effects in mice[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | ||||||||||||
| CAS | 1541207-06-0 | ||||||||||||
| Formula | C28H22O4 | ||||||||||||
| Molar Mass | 422.47 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Berger WT, et al. Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS One. 2012;7(12):e50968. [2]. Hsu HC, et al. The Antinociceptive Agent SBFI-26 Binds to Anandamide Transporters FABP5 and FABP7 at Two Different Sites. Biochemistry. 2017 Jul 11;56(27):3454-3462. |